Andrew Donson
Concepts (423)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ependymoma | 27 | 2025 | 163 | 5.400 |
Why?
| | Brain Neoplasms | 44 | 2025 | 1266 | 4.140 |
Why?
| | Infratentorial Neoplasms | 8 | 2025 | 64 | 2.360 |
Why?
| | Glioma | 18 | 2025 | 402 | 2.170 |
Why?
| | Astrocytoma | 13 | 2025 | 127 | 1.590 |
Why?
| | Medulloblastoma | 15 | 2023 | 193 | 1.580 |
Why?
| | Gene Expression Regulation, Neoplastic | 26 | 2025 | 1385 | 1.510 |
Why?
| | Craniopharyngioma | 7 | 2024 | 73 | 1.390 |
Why?
| | Glioblastoma | 14 | 2019 | 340 | 1.380 |
Why?
| | Brain Stem Neoplasms | 9 | 2023 | 83 | 1.330 |
Why?
| | Gene Expression Profiling | 26 | 2024 | 1752 | 1.260 |
Why?
| | Cerebellar Neoplasms | 9 | 2023 | 153 | 1.150 |
Why?
| | Rhabdoid Tumor | 11 | 2025 | 99 | 1.150 |
Why?
| | Pituitary Neoplasms | 5 | 2024 | 189 | 1.040 |
Why?
| | Ganglioglioma | 5 | 2025 | 34 | 0.990 |
Why?
| | Proto-Oncogene Proteins B-raf | 6 | 2025 | 222 | 0.900 |
Why?
| | Central Nervous System Neoplasms | 9 | 2021 | 155 | 0.890 |
Why?
| | Biomarkers, Tumor | 12 | 2024 | 1233 | 0.750 |
Why?
| | Drug Screening Assays, Antitumor | 5 | 2021 | 193 | 0.710 |
Why?
| | Cell Line, Tumor | 28 | 2025 | 3400 | 0.700 |
Why?
| | Transcriptome | 11 | 2025 | 969 | 0.660 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2020 | 79 | 0.630 |
Why?
| | Radiation Tolerance | 6 | 2022 | 96 | 0.630 |
Why?
| | Neoplasm Recurrence, Local | 8 | 2021 | 1038 | 0.610 |
Why?
| | Single-Cell Analysis | 2 | 2021 | 324 | 0.570 |
Why?
| | Child | 49 | 2025 | 21833 | 0.560 |
Why?
| | Tumor Microenvironment | 7 | 2025 | 668 | 0.550 |
Why?
| | Cyst Fluid | 1 | 2017 | 21 | 0.550 |
Why?
| | Antineoplastic Agents | 7 | 2022 | 2128 | 0.510 |
Why?
| | Oligonucleotide Array Sequence Analysis | 19 | 2016 | 757 | 0.500 |
Why?
| | Radiation | 3 | 2021 | 25 | 0.490 |
Why?
| | Teratoma | 6 | 2022 | 118 | 0.470 |
Why?
| | Cell Cycle Proteins | 6 | 2022 | 614 | 0.470 |
Why?
| | Humans | 104 | 2025 | 137601 | 0.470 |
Why?
| | Chromosomes, Human, Pair 1 | 3 | 2020 | 71 | 0.450 |
Why?
| | Nuclear Proteins | 5 | 2025 | 708 | 0.450 |
Why?
| | Cancer Vaccines | 2 | 2010 | 165 | 0.430 |
Why?
| | DNA Methylation | 7 | 2021 | 637 | 0.420 |
Why?
| | Child, Preschool | 30 | 2025 | 11102 | 0.400 |
Why?
| | SMARCB1 Protein | 2 | 2025 | 30 | 0.380 |
Why?
| | Cell Proliferation | 18 | 2025 | 2467 | 0.370 |
Why?
| | Radiation-Sensitizing Agents | 3 | 2016 | 43 | 0.370 |
Why?
| | Cytokines | 4 | 2018 | 2075 | 0.360 |
Why?
| | Apoptosis | 15 | 2025 | 2551 | 0.350 |
Why?
| | Neoplasm Proteins | 3 | 2012 | 429 | 0.350 |
Why?
| | Neoplasms, Neuroepithelial | 2 | 2021 | 15 | 0.340 |
Why?
| | Tumor Suppressor Proteins | 2 | 2017 | 323 | 0.340 |
Why?
| | Survivors | 2 | 2023 | 499 | 0.330 |
Why?
| | Chromosome Aberrations | 2 | 2023 | 157 | 0.320 |
Why?
| | Mutation | 9 | 2025 | 3991 | 0.320 |
Why?
| | Prognosis | 15 | 2023 | 3966 | 0.320 |
Why?
| | Supratentorial Neoplasms | 2 | 2021 | 16 | 0.320 |
Why?
| | Protein-Tyrosine Kinases | 4 | 2019 | 424 | 0.310 |
Why?
| | Histones | 4 | 2021 | 636 | 0.310 |
Why?
| | Proto-Oncogene Proteins | 5 | 2022 | 623 | 0.300 |
Why?
| | Microarray Analysis | 7 | 2017 | 116 | 0.300 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2021 | 206 | 0.300 |
Why?
| | Quinazolines | 3 | 2022 | 249 | 0.300 |
Why?
| | Tumor Cells, Cultured | 9 | 2025 | 945 | 0.290 |
Why?
| | Pyrimidines | 6 | 2017 | 462 | 0.290 |
Why?
| | Drug Resistance, Neoplasm | 5 | 2017 | 793 | 0.280 |
Why?
| | MAP Kinase Signaling System | 2 | 2021 | 322 | 0.280 |
Why?
| | NF-kappa B | 3 | 2025 | 678 | 0.270 |
Why?
| | DNA Modification Methylases | 1 | 2007 | 17 | 0.270 |
Why?
| | DNA Repair Enzymes | 1 | 2007 | 28 | 0.260 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2020 | 1706 | 0.260 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2007 | 69 | 0.260 |
Why?
| | Chemoradiotherapy | 2 | 2019 | 229 | 0.260 |
Why?
| | Dacarbazine | 1 | 2007 | 96 | 0.260 |
Why?
| | Cyclin-Dependent Kinase 6 | 2 | 2020 | 42 | 0.260 |
Why?
| | Chromosomes | 2 | 2024 | 106 | 0.250 |
Why?
| | B7-H1 Antigen | 2 | 2018 | 216 | 0.240 |
Why?
| | Immunohistochemistry | 6 | 2017 | 1718 | 0.240 |
Why?
| | Infant | 17 | 2020 | 9539 | 0.240 |
Why?
| | RNA, Messenger | 8 | 2017 | 2798 | 0.240 |
Why?
| | Chloroquine | 2 | 2017 | 52 | 0.240 |
Why?
| | Chromatin | 3 | 2025 | 517 | 0.240 |
Why?
| | 12E7 Antigen | 1 | 2025 | 10 | 0.240 |
Why?
| | Adolescent | 24 | 2025 | 21435 | 0.230 |
Why?
| | Sirtuin 2 | 1 | 2025 | 24 | 0.230 |
Why?
| | Kaplan-Meier Estimate | 5 | 2021 | 887 | 0.230 |
Why?
| | Mice | 16 | 2025 | 17748 | 0.220 |
Why?
| | DNA, Neoplasm | 2 | 2020 | 157 | 0.220 |
Why?
| | Cellular Senescence | 2 | 2024 | 190 | 0.220 |
Why?
| | Cisplatin | 3 | 2016 | 325 | 0.220 |
Why?
| | Immunophenotyping | 2 | 2017 | 324 | 0.220 |
Why?
| | Molecular Targeted Therapy | 3 | 2018 | 408 | 0.220 |
Why?
| | Macrophage Activation | 1 | 2025 | 199 | 0.220 |
Why?
| | Neoplasms, Radiation-Induced | 3 | 2010 | 91 | 0.210 |
Why?
| | Male | 36 | 2025 | 67690 | 0.210 |
Why?
| | Female | 37 | 2025 | 73359 | 0.210 |
Why?
| | Neurofibroma, Plexiform | 1 | 2023 | 11 | 0.210 |
Why?
| | Phagocytosis | 1 | 2025 | 387 | 0.200 |
Why?
| | Pyrazoles | 5 | 2022 | 421 | 0.200 |
Why?
| | Neurofibromatosis 1 | 1 | 2023 | 56 | 0.200 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 2 | 2021 | 44 | 0.200 |
Why?
| | Autophagy | 2 | 2017 | 286 | 0.200 |
Why?
| | Transcription Factors | 5 | 2023 | 1706 | 0.200 |
Why?
| | Epigenesis, Genetic | 4 | 2021 | 646 | 0.200 |
Why?
| | Survival Analysis | 3 | 2023 | 1289 | 0.190 |
Why?
| | Tamoxifen | 2 | 2004 | 201 | 0.190 |
Why?
| | Indoles | 2 | 2017 | 409 | 0.190 |
Why?
| | Cell Survival | 8 | 2020 | 1128 | 0.190 |
Why?
| | raf Kinases | 1 | 2021 | 12 | 0.180 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2021 | 16 | 0.180 |
Why?
| | Sulfonamides | 2 | 2017 | 508 | 0.180 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 66 | 0.180 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 67 | 0.180 |
Why?
| | Receptor, ErbB-3 | 2 | 2015 | 44 | 0.180 |
Why?
| | Receptor, trkC | 1 | 2021 | 11 | 0.180 |
Why?
| | Gene Amplification | 1 | 2021 | 103 | 0.180 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2023 | 211 | 0.170 |
Why?
| | Cell Cycle | 8 | 2017 | 598 | 0.170 |
Why?
| | Receptors, Fibroblast Growth Factor | 1 | 2021 | 68 | 0.170 |
Why?
| | Cohort Studies | 9 | 2021 | 5691 | 0.170 |
Why?
| | Vaccination | 1 | 2010 | 1430 | 0.170 |
Why?
| | Receptor, trkB | 1 | 2021 | 33 | 0.170 |
Why?
| | Gene Expression | 4 | 2015 | 1485 | 0.170 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 1 | 2021 | 62 | 0.170 |
Why?
| | Polycomb Repressive Complex 1 | 1 | 2020 | 50 | 0.160 |
Why?
| | Animals | 17 | 2025 | 37088 | 0.160 |
Why?
| | B7 Antigens | 1 | 2020 | 14 | 0.160 |
Why?
| | Anilides | 2 | 2010 | 72 | 0.160 |
Why?
| | DNA-Binding Proteins | 3 | 2021 | 1475 | 0.160 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2020 | 90 | 0.160 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2019 | 328 | 0.160 |
Why?
| | Phenotype | 5 | 2024 | 3150 | 0.160 |
Why?
| | MicroRNAs | 2 | 2020 | 676 | 0.160 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 7 | 2012 | 978 | 0.150 |
Why?
| | Cell Lineage | 1 | 2021 | 352 | 0.150 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2012 | 206 | 0.150 |
Why?
| | Genome, Human | 3 | 2021 | 418 | 0.150 |
Why?
| | Pteridines | 2 | 2016 | 20 | 0.150 |
Why?
| | Machine Learning | 1 | 2024 | 516 | 0.150 |
Why?
| | Protein Kinase C | 1 | 2000 | 254 | 0.150 |
Why?
| | Infant, Newborn | 8 | 2020 | 6125 | 0.140 |
Why?
| | Membrane Glycoproteins | 1 | 2021 | 500 | 0.140 |
Why?
| | Antibodies, Monoclonal | 1 | 2025 | 1425 | 0.140 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2017 | 2022 | 0.140 |
Why?
| | ErbB Receptors | 2 | 2015 | 611 | 0.140 |
Why?
| | Stromal Cells | 1 | 2018 | 111 | 0.140 |
Why?
| | Aging | 2 | 2020 | 1850 | 0.140 |
Why?
| | Adenoviridae | 1 | 1998 | 198 | 0.140 |
Why?
| | SOXE Transcription Factors | 2 | 2016 | 21 | 0.140 |
Why?
| | Drug Approval | 1 | 2018 | 87 | 0.140 |
Why?
| | Meningioma | 2 | 2009 | 94 | 0.140 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 524 | 0.140 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2019 | 139 | 0.140 |
Why?
| | Computer Simulation | 2 | 2021 | 987 | 0.140 |
Why?
| | Macrophages | 1 | 2025 | 1544 | 0.140 |
Why?
| | Transcription Factor RelA | 1 | 2018 | 85 | 0.140 |
Why?
| | Receptors, Interleukin-6 | 1 | 2017 | 45 | 0.130 |
Why?
| | Genes, p16 | 1 | 2017 | 17 | 0.130 |
Why?
| | Everolimus | 1 | 2017 | 98 | 0.130 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 57 | 0.130 |
Why?
| | E2F Transcription Factors | 1 | 2017 | 60 | 0.130 |
Why?
| | Spinal Neoplasms | 1 | 2017 | 34 | 0.130 |
Why?
| | Morpholines | 1 | 2017 | 123 | 0.130 |
Why?
| | Stem Cells | 1 | 2021 | 597 | 0.130 |
Why?
| | Checkpoint Kinase 1 | 1 | 2016 | 28 | 0.130 |
Why?
| | Genetic Therapy | 1 | 1998 | 311 | 0.130 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2020 | 748 | 0.120 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2018 | 253 | 0.120 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2021 | 873 | 0.120 |
Why?
| | Blotting, Western | 6 | 2013 | 1221 | 0.120 |
Why?
| | Myeloid Cells | 2 | 2015 | 150 | 0.120 |
Why?
| | Bone Morphogenetic Proteins | 2 | 2019 | 138 | 0.120 |
Why?
| | Retrospective Studies | 11 | 2020 | 15720 | 0.120 |
Why?
| | EGF Family of Proteins | 1 | 2015 | 17 | 0.120 |
Why?
| | Receptor, EphA2 | 1 | 2015 | 16 | 0.120 |
Why?
| | Neuroectodermal Tumors, Primitive | 2 | 2012 | 11 | 0.120 |
Why?
| | Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2015 | 20 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2017 | 442 | 0.120 |
Why?
| | Pilomatrixoma | 1 | 2015 | 3 | 0.120 |
Why?
| | Young Adult | 9 | 2021 | 13203 | 0.120 |
Why?
| | Flow Cytometry | 3 | 2006 | 1193 | 0.110 |
Why?
| | Disease Models, Animal | 3 | 2021 | 4301 | 0.110 |
Why?
| | Radiation, Ionizing | 2 | 2012 | 80 | 0.110 |
Why?
| | Proteins | 1 | 2021 | 1011 | 0.110 |
Why?
| | Mutation, Missense | 1 | 2016 | 340 | 0.110 |
Why?
| | src-Family Kinases | 1 | 2015 | 93 | 0.110 |
Why?
| | Genetic Variation | 1 | 2019 | 1001 | 0.110 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2025 | 864 | 0.110 |
Why?
| | Activin Receptors, Type I | 1 | 2014 | 8 | 0.110 |
Why?
| | Follow-Up Studies | 6 | 2020 | 5121 | 0.110 |
Why?
| | Drug Delivery Systems | 2 | 2015 | 357 | 0.110 |
Why?
| | Deoxyribose | 1 | 2013 | 6 | 0.100 |
Why?
| | Glutamate-Cysteine Ligase | 1 | 2013 | 20 | 0.100 |
Why?
| | STAT3 Transcription Factor | 1 | 2015 | 203 | 0.100 |
Why?
| | Adult | 16 | 2023 | 37910 | 0.100 |
Why?
| | RNA-Binding Proteins | 2 | 2015 | 427 | 0.100 |
Why?
| | Survival Rate | 4 | 2020 | 1906 | 0.100 |
Why?
| | Acetylcysteine | 1 | 2013 | 145 | 0.100 |
Why?
| | Karyotyping | 4 | 2010 | 104 | 0.100 |
Why?
| | Exons | 1 | 2013 | 353 | 0.100 |
Why?
| | Karnofsky Performance Status | 1 | 2012 | 36 | 0.100 |
Why?
| | Receptors, Opioid | 1 | 2012 | 26 | 0.090 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2012 | 57 | 0.090 |
Why?
| | Pons | 1 | 2012 | 29 | 0.090 |
Why?
| | Central Nervous System | 1 | 2014 | 262 | 0.090 |
Why?
| | Combined Modality Therapy | 4 | 2019 | 1226 | 0.090 |
Why?
| | Cell Differentiation | 4 | 2025 | 1999 | 0.090 |
Why?
| | Tomography, X-Ray Computed | 2 | 2020 | 2679 | 0.090 |
Why?
| | Protein Precursors | 1 | 2012 | 133 | 0.090 |
Why?
| | Age Factors | 2 | 2017 | 3253 | 0.090 |
Why?
| | RNA, Small Interfering | 2 | 2010 | 619 | 0.090 |
Why?
| | Databases, Factual | 1 | 2016 | 1382 | 0.090 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2011 | 174 | 0.080 |
Why?
| | Interleukin-6 | 1 | 2015 | 785 | 0.080 |
Why?
| | Protein Kinase Inhibitors | 3 | 2014 | 905 | 0.080 |
Why?
| | Drug Synergism | 3 | 2017 | 369 | 0.080 |
Why?
| | Acetaminophen | 1 | 2013 | 265 | 0.080 |
Why?
| | Epigenomics | 2 | 2021 | 115 | 0.080 |
Why?
| | Risk Factors | 4 | 2020 | 10319 | 0.080 |
Why?
| | Cluster Analysis | 3 | 2021 | 512 | 0.080 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2011 | 207 | 0.080 |
Why?
| | Neoplasm Grading | 2 | 2021 | 304 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 2 | 2020 | 3607 | 0.080 |
Why?
| | Peripheral Nervous System Neoplasms | 1 | 2009 | 18 | 0.080 |
Why?
| | Spinal Cord Neoplasms | 1 | 2009 | 37 | 0.080 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2009 | 98 | 0.080 |
Why?
| | Hemangioma | 1 | 2009 | 44 | 0.080 |
Why?
| | Astrocytes | 1 | 2011 | 211 | 0.080 |
Why?
| | T-Lymphocytes | 2 | 2018 | 1979 | 0.080 |
Why?
| | Signal Transduction | 3 | 2025 | 5060 | 0.080 |
Why?
| | Proportional Hazards Models | 1 | 2012 | 1272 | 0.070 |
Why?
| | Gene Ontology | 2 | 2021 | 54 | 0.070 |
Why?
| | Enzyme Inhibitors | 4 | 2012 | 847 | 0.070 |
Why?
| | Kidney Neoplasms | 1 | 2013 | 403 | 0.070 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2010 | 231 | 0.070 |
Why?
| | Sarcoma, Ewing | 1 | 2009 | 100 | 0.070 |
Why?
| | Glucose | 1 | 2013 | 1032 | 0.070 |
Why?
| | Herpesvirus 3, Human | 1 | 2011 | 331 | 0.070 |
Why?
| | Herpes Zoster | 1 | 2011 | 314 | 0.070 |
Why?
| | DNA Copy Number Variations | 2 | 2021 | 178 | 0.070 |
Why?
| | Mesenchymoma | 1 | 2007 | 9 | 0.070 |
Why?
| | Nerve Sheath Neoplasms | 1 | 2007 | 12 | 0.070 |
Why?
| | Meningeal Neoplasms | 1 | 2008 | 102 | 0.070 |
Why?
| | Phosphorylation | 3 | 2017 | 1760 | 0.070 |
Why?
| | Aurora Kinases | 3 | 2012 | 28 | 0.070 |
Why?
| | Real-Time Polymerase Chain Reaction | 3 | 2012 | 348 | 0.060 |
Why?
| | Etoposide | 1 | 2007 | 160 | 0.060 |
Why?
| | Thymidine | 1 | 2006 | 59 | 0.060 |
Why?
| | Aurora Kinase A | 3 | 2012 | 57 | 0.060 |
Why?
| | High Mobility Group Proteins | 1 | 2006 | 44 | 0.060 |
Why?
| | Gene Silencing | 1 | 2007 | 197 | 0.060 |
Why?
| | Dose-Response Relationship, Radiation | 2 | 2012 | 143 | 0.060 |
Why?
| | Piperazines | 2 | 2022 | 343 | 0.060 |
Why?
| | Nerve Tissue Proteins | 1 | 2009 | 596 | 0.060 |
Why?
| | CD47 Antigen | 1 | 2025 | 38 | 0.060 |
Why?
| | Azepines | 2 | 2019 | 97 | 0.060 |
Why?
| | In Situ Hybridization, Fluorescence | 3 | 2012 | 308 | 0.060 |
Why?
| | Fatal Outcome | 2 | 2021 | 309 | 0.060 |
Why?
| | Coculture Techniques | 2 | 2011 | 240 | 0.060 |
Why?
| | Computational Biology | 2 | 2020 | 649 | 0.050 |
Why?
| | Treatment Outcome | 3 | 2024 | 10813 | 0.050 |
Why?
| | Pyrimidinones | 2 | 2016 | 111 | 0.050 |
Why?
| | Cell Division | 2 | 2010 | 790 | 0.050 |
Why?
| | Benzamides | 2 | 2017 | 206 | 0.050 |
Why?
| | X-ray Repair Cross Complementing Protein 1 | 1 | 2023 | 13 | 0.050 |
Why?
| | Intelligence Tests | 1 | 2023 | 56 | 0.050 |
Why?
| | RNA, Small Nuclear | 1 | 2023 | 37 | 0.050 |
Why?
| | Fluorouracil | 1 | 2024 | 201 | 0.050 |
Why?
| | Cranial Irradiation | 1 | 2023 | 85 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 2023 | 39 | 0.050 |
Why?
| | Quality of Life | 1 | 2015 | 2942 | 0.050 |
Why?
| | Caspases | 1 | 2004 | 243 | 0.050 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2004 | 168 | 0.050 |
Why?
| | Up-Regulation | 2 | 2016 | 843 | 0.050 |
Why?
| | Cytidine Deaminase | 1 | 2023 | 61 | 0.050 |
Why?
| | Genomics | 2 | 2021 | 803 | 0.050 |
Why?
| | Membrane Proteins | 1 | 2009 | 1152 | 0.050 |
Why?
| | Brain Stem | 1 | 2023 | 96 | 0.050 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2022 | 44 | 0.050 |
Why?
| | RNA | 2 | 2023 | 926 | 0.050 |
Why?
| | Transcription, Genetic | 2 | 2021 | 1455 | 0.050 |
Why?
| | Sequence Analysis, DNA | 2 | 2016 | 826 | 0.050 |
Why?
| | Middle Aged | 7 | 2021 | 33441 | 0.050 |
Why?
| | Septum Pellucidum | 1 | 2021 | 5 | 0.050 |
Why?
| | Cerebellum | 1 | 2023 | 216 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2006 | 1941 | 0.040 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2021 | 14 | 0.040 |
Why?
| | Histone Deacetylases | 1 | 2023 | 210 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 665 | 0.040 |
Why?
| | Mesencephalon | 1 | 2021 | 66 | 0.040 |
Why?
| | Pancreatic Neoplasms | 1 | 2009 | 853 | 0.040 |
Why?
| | Chromosome Deletion | 1 | 2021 | 114 | 0.040 |
Why?
| | Disease Progression | 2 | 2023 | 2722 | 0.040 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2013 | 190 | 0.040 |
Why?
| | Genetic Heterogeneity | 1 | 2021 | 59 | 0.040 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2021 | 53 | 0.040 |
Why?
| | Neoplasm Staging | 2 | 2017 | 1359 | 0.040 |
Why?
| | DNA Damage | 2 | 2016 | 422 | 0.040 |
Why?
| | Gene Rearrangement | 1 | 2021 | 150 | 0.040 |
Why?
| | Hedgehog Proteins | 1 | 2022 | 199 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2021 | 183 | 0.040 |
Why?
| | Vinblastine | 1 | 2020 | 70 | 0.040 |
Why?
| | Preoperative Period | 1 | 2020 | 135 | 0.040 |
Why?
| | Cell Fusion | 1 | 2020 | 51 | 0.040 |
Why?
| | Carboplatin | 1 | 2020 | 144 | 0.040 |
Why?
| | Signal-To-Noise Ratio | 1 | 2020 | 64 | 0.040 |
Why?
| | Repressor Proteins | 1 | 2023 | 423 | 0.040 |
Why?
| | RNA, Neoplasm | 2 | 2009 | 79 | 0.040 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 1998 | 39 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2023 | 1046 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 368 | 0.040 |
Why?
| | Cell Self Renewal | 1 | 2019 | 56 | 0.040 |
Why?
| | Pyridines | 2 | 2012 | 498 | 0.040 |
Why?
| | Protein Isoforms | 1 | 2000 | 391 | 0.040 |
Why?
| | Benchmarking | 1 | 2020 | 186 | 0.040 |
Why?
| | Odontogenesis | 1 | 2018 | 11 | 0.040 |
Why?
| | Lysine | 1 | 2020 | 288 | 0.040 |
Why?
| | Laser Capture Microdissection | 1 | 2018 | 32 | 0.040 |
Why?
| | In Vitro Techniques | 1 | 2020 | 1088 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 596 | 0.030 |
Why?
| | Treatment Failure | 1 | 1999 | 346 | 0.030 |
Why?
| | Tissue Culture Techniques | 1 | 2018 | 82 | 0.030 |
Why?
| | Receptors, HIV | 1 | 2017 | 25 | 0.030 |
Why?
| | Down-Regulation | 1 | 2000 | 635 | 0.030 |
Why?
| | Mucin-1 | 1 | 2017 | 21 | 0.030 |
Why?
| | Triazoles | 1 | 2019 | 155 | 0.030 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2017 | 62 | 0.030 |
Why?
| | Cytogenetic Analysis | 1 | 2017 | 33 | 0.030 |
Why?
| | Pituitary Gland | 1 | 2018 | 146 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 2018 | 384 | 0.030 |
Why?
| | Immune System | 1 | 1998 | 181 | 0.030 |
Why?
| | Genetic Vectors | 1 | 1998 | 335 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2020 | 730 | 0.030 |
Why?
| | Interleukin-2 | 1 | 1998 | 451 | 0.030 |
Why?
| | Ki-67 Antigen | 1 | 2017 | 109 | 0.030 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 126 | 0.030 |
Why?
| | Mice, Nude | 1 | 2019 | 688 | 0.030 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2017 | 100 | 0.030 |
Why?
| | Cetuximab | 1 | 2017 | 98 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2020 | 578 | 0.030 |
Why?
| | Neuroglia | 1 | 2018 | 171 | 0.030 |
Why?
| | Benzodiazepinones | 1 | 2016 | 18 | 0.030 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2016 | 24 | 0.030 |
Why?
| | Diagnosis, Differential | 2 | 2012 | 1488 | 0.030 |
Why?
| | Camptothecin | 1 | 2017 | 121 | 0.030 |
Why?
| | Genes, myc | 1 | 2016 | 48 | 0.030 |
Why?
| | Immune Tolerance | 1 | 1998 | 366 | 0.030 |
Why?
| | Urea | 1 | 2016 | 78 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2017 | 322 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 541 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2021 | 2165 | 0.030 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 1998 | 388 | 0.030 |
Why?
| | Thiophenes | 1 | 2016 | 120 | 0.030 |
Why?
| | Antigens, CD | 1 | 1998 | 530 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2016 | 307 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2017 | 373 | 0.030 |
Why?
| | Amphiregulin | 1 | 2015 | 25 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 451 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 1998 | 1350 | 0.030 |
Why?
| | Gene Fusion | 1 | 2015 | 26 | 0.030 |
Why?
| | Mitosis | 1 | 2016 | 191 | 0.030 |
Why?
| | Cell Culture Techniques | 1 | 2017 | 363 | 0.030 |
Why?
| | HeLa Cells | 1 | 2016 | 635 | 0.030 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2015 | 89 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 672 | 0.030 |
Why?
| | Gene Dosage | 1 | 2015 | 142 | 0.030 |
Why?
| | Inhibitor of Differentiation Protein 2 | 1 | 2014 | 5 | 0.030 |
Why?
| | Inhibitor of Differentiation Protein 1 | 1 | 2014 | 8 | 0.030 |
Why?
| | Smad Proteins | 1 | 2014 | 43 | 0.030 |
Why?
| | Aged | 4 | 2016 | 23938 | 0.030 |
Why?
| | Receptors, IgG | 1 | 2013 | 77 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2013 | 73 | 0.030 |
Why?
| | Imaging, Three-Dimensional | 1 | 2017 | 564 | 0.030 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2013 | 143 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2017 | 1236 | 0.020 |
Why?
| | Algorithms | 1 | 2020 | 1701 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2013 | 338 | 0.020 |
Why?
| | Phosphoproteins | 1 | 2015 | 340 | 0.020 |
Why?
| | HLA-DR Antigens | 1 | 2013 | 228 | 0.020 |
Why?
| | Catalysis | 1 | 2013 | 317 | 0.020 |
Why?
| | Monocytes | 1 | 2015 | 563 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2015 | 430 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2015 | 511 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2020 | 3287 | 0.020 |
Why?
| | Colorado | 1 | 2022 | 4515 | 0.020 |
Why?
| | Glutathione | 1 | 2013 | 356 | 0.020 |
Why?
| | Tubulin | 1 | 2012 | 145 | 0.020 |
Why?
| | Acetylation | 1 | 2011 | 245 | 0.020 |
Why?
| | Neural Stem Cells | 1 | 2012 | 156 | 0.020 |
Why?
| | RNA Interference | 1 | 2012 | 468 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 5764 | 0.020 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2010 | 41 | 0.020 |
Why?
| | Choroid Plexus Neoplasms | 1 | 2009 | 8 | 0.020 |
Why?
| | Papilloma | 1 | 2009 | 51 | 0.020 |
Why?
| | Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2009 | 11 | 0.020 |
Why?
| | Kinetics | 1 | 2013 | 1640 | 0.020 |
Why?
| | Zebrafish | 1 | 2014 | 500 | 0.020 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2009 | 50 | 0.020 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2009 | 83 | 0.020 |
Why?
| | Epilepsy | 1 | 2013 | 335 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2010 | 328 | 0.020 |
Why?
| | Antibodies, Neoplasm | 1 | 2009 | 34 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2009 | 283 | 0.020 |
Why?
| | Claudins | 1 | 2009 | 24 | 0.020 |
Why?
| | Cytogenetics | 1 | 2008 | 10 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 2011 | 568 | 0.020 |
Why?
| | Virus Replication | 1 | 2011 | 528 | 0.020 |
Why?
| | DNA Repair | 1 | 2009 | 231 | 0.020 |
Why?
| | Paresis | 1 | 2007 | 30 | 0.020 |
Why?
| | Biopsy | 1 | 2010 | 1089 | 0.020 |
Why?
| | Inflammation | 1 | 2018 | 2841 | 0.020 |
Why?
| | Hypothalamic Neoplasms | 1 | 2006 | 9 | 0.020 |
Why?
| | Craniotomy | 1 | 2007 | 77 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 2007 | 435 | 0.020 |
Why?
| | Multigene Family | 1 | 2007 | 200 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2143 | 0.020 |
Why?
| | Genetic Linkage | 1 | 2006 | 292 | 0.010 |
Why?
| | Vision Disorders | 1 | 2007 | 155 | 0.010 |
Why?
| | Neural Crest | 1 | 2006 | 121 | 0.010 |
Why?
| | Genetic Markers | 1 | 2006 | 345 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2007 | 360 | 0.010 |
Why?
| | Caspase 3 | 1 | 2004 | 249 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2004 | 818 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2013 | 7609 | 0.010 |
Why?
| | Brain | 1 | 2013 | 2725 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2006 | 2365 | 0.010 |
Why?
| | Time Factors | 1 | 2008 | 6818 | 0.010 |
Why?
| | Neoplasms | 1 | 2008 | 2691 | 0.010 |
Why?
|
|
Donson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|